Centaur Biopharma to manufacture COVID-19 vaccine for Vaxart

By The Science Advisory Board staff writers

October 7, 2020 -- Centaur Biopharmaceutical Services has expanded its manufacturing agreement with Vaxart to manufacture Vaxart's oral COVID-19 vaccine.

As a contract development and manufacturing organization, Centaur will provide its expertise in protein-based biologics and virus-based product manufacturing. The company, a subsidiary of KindredBio, has facilities in California and Kansas.

Under the terms of the extended agreement, Centaur will be responsible for scaling the COVID-19 clinical trial material into mid-size bioreactors at its California plant, and manufacturing at 2000-L scale in single-use bioreactors at its Kansas plant.

Vaxart received investigational new drug application clearance for its phase I clinical trial evaluating its oral COVID-19 vaccine candidate on September 14.

Oragenics moves ahead with SARS-CoV-2 vaccine
Oragenics is moving ahead with its SARS-CoV-2 vaccine called Terra CoV-2 with the support of the U.S. Food and Drug Administration.
Allele Biotech supports COVID-19 vaccine manufacturing
Allele Biotechnology and Pharmaceuticals' current good manufacturing practices-grade induced pluripotent stem cells are being used as packaging factories...
Moderna touts positive vaccine results in older populations
Results from Moderna's phase I clinical trial indicated that its candidate for a COVID-19 vaccine, messenger RNA (mRNA)-1273, is well-tolerated and generates...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter